CAR-T Cell Therapy Shows Durable 3-Year Benefits in Lymphoma Treatment
Lisocabtagene maraleucel demonstrates superior long-term survival compared to standard chemotherapy in relapsed B-cell lymphoma patients.
Summary
A 3-year follow-up of the TRANSFORM trial shows that lisocabtagene maraleucel (liso-cel), a CAR-T cell therapy, provides superior and more durable treatment outcomes compared to standard chemotherapy for patients with relapsed/refractory large B-cell lymphoma. The study found that patients receiving liso-cel had significantly longer event-free survival (29.5 vs 2.4 months) and progression-free survival, with 51% remaining progression-free at 36 months compared to 26.5% with standard care. These results support CAR-T therapy as an effective second-line treatment with curative potential for this challenging cancer.
Detailed Summary
The TRANSFORM trial's 3-year follow-up data provides compelling evidence for the long-term superiority of CAR-T cell therapy in treating relapsed/refractory large B-cell lymphoma, a particularly aggressive form of blood cancer that has historically been difficult to cure.
This randomized phase III study compared lisocabtagene maraleucel (liso-cel), a personalized CAR-T cell therapy, against standard chemotherapy followed by stem cell transplantation in 184 patients whose lymphoma had either never responded to initial treatment or relapsed within 12 months. The treatment involves extracting a patient's T cells, genetically modifying them to better recognize and attack cancer cells, then reinfusing them.
With a median follow-up of nearly 3 years, the results demonstrate remarkable durability of CAR-T therapy benefits. Patients receiving liso-cel experienced a median event-free survival of 29.5 months compared to just 2.4 months with standard care. Most strikingly, 51% of CAR-T patients remained progression-free at 36 months versus only 26.5% in the standard care group. The median progression-free survival wasn't even reached in the CAR-T group, indicating many patients may be cured.
While overall survival showed numerical improvement favoring CAR-T therapy, the comparison was complicated by 66% of standard care patients crossing over to receive liso-cel when their initial treatment failed. When accounting for this crossover effect, the survival benefit became statistically significant, suggesting CAR-T therapy's true impact may be even greater.
These findings represent a paradigm shift in lymphoma treatment, offering hope for durable remissions in patients who previously faced poor prognoses. The safety profile remained consistent with previous reports, with no new concerning signals emerging over the extended follow-up period.
Key Findings
- CAR-T therapy extended event-free survival to 29.5 months vs 2.4 months with standard care
- 51% of CAR-T patients remained progression-free at 3 years vs 26.5% with chemotherapy
- Median progression-free survival not reached with CAR-T, suggesting potential cures
- 66% of standard care patients crossed over to receive CAR-T after treatment failure
- No new safety concerns emerged during 3-year follow-up period
Methodology
This was a randomized, open-label phase III trial comparing liso-cel CAR-T therapy (100×10⁶ CAR+ T cells) versus standard immunochemotherapy followed by autologous stem cell transplantation in 184 adults with primary refractory or early relapsed large B-cell lymphoma. Patients were followed for a median of 33.9 months with crossover allowed from standard care to CAR-T therapy.
Study Limitations
The high crossover rate (66%) from standard care to CAR-T therapy complicated overall survival comparisons, though statistical methods accounting for crossover still favored CAR-T. The study was open-label, and long-term safety data beyond 3 years remains limited. Results may not generalize to all lymphoma subtypes or patient populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.